Technical Analysis for TOVX - Theriva Biologics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.41 | -2.15% | -0.01 |
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.15% | |
20 DMA Support | Bullish | -2.15% | |
NR7 | Range Contraction | -2.15% | |
Inside Day | Range Contraction | -2.15% | |
Gapped Down | Weakness | -2.15% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.91% | |
Crossed Above 20 DMA | Bullish | -1.91% | |
20 DMA Resistance | Bearish | 2.50% | |
Outside Day | Range Expansion | 2.50% | |
Gapped Down | Weakness | 2.50% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 8 minutes ago |
Fell Below 20 DMA | 8 minutes ago |
Fell Below 10 DMA | 8 minutes ago |
Reversed from Up | 8 minutes ago |
10 DMA Support | about 2 hours ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
Theriva Biologics, Inc. Description
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Life Sciences Disease Infection Antibiotics Colorectal Cancer Pancreatic Cancer Diarrhea Bacterial Disease Pathogenic Bacteria Clostridium Difficile Infection Head And Neck Squamous Cell Carcinoma Gram Positive Bacteria
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.2 |
52 Week Low | 0.1972 |
Average Volume | 151,880 |
200-Day Moving Average | 0.49 |
50-Day Moving Average | 0.45 |
20-Day Moving Average | 0.42 |
10-Day Moving Average | 0.41 |
Average True Range | 0.04 |
RSI (14) | 47.92 |
ADX | 14.83 |
+DI | 15.90 |
-DI | 14.83 |
Chandelier Exit (Long, 3 ATRs) | 0.35 |
Chandelier Exit (Short, 3 ATRs) | 0.45 |
Upper Bollinger Bands | 0.46 |
Lower Bollinger Band | 0.38 |
Percent B (%b) | 0.53 |
BandWidth | 19.41 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0027 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.46 | ||||
Resistance 3 (R3) | 0.46 | 0.44 | 0.45 | ||
Resistance 2 (R2) | 0.44 | 0.43 | 0.44 | 0.45 | |
Resistance 1 (R1) | 0.43 | 0.42 | 0.44 | 0.43 | 0.45 |
Pivot Point | 0.41 | 0.41 | 0.42 | 0.42 | 0.41 |
Support 1 (S1) | 0.40 | 0.41 | 0.41 | 0.41 | 0.39 |
Support 2 (S2) | 0.39 | 0.40 | 0.39 | 0.39 | |
Support 3 (S3) | 0.38 | 0.39 | 0.39 | ||
Support 4 (S4) | 0.38 |